Intellipharmaceutics Announces Resignation of Chief Financial Officer
08 août 2017 15h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit
31 juil. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
26 juil. 2017 20h15 HE
|
Intellipharmaceutics International Inc.
TORONTO, July 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Second Quarter 2017 Results
11 juil. 2017 17h15 HE
|
Intellipharmaceutics International Inc.
TORONTO, July 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
30 juin 2017 16h05 HE
|
Intellipharmaceutics International Inc.
TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt
06 juin 2017 08h50 HE
|
Intellipharmaceutics International Inc.
TORONTO, June 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
26 mai 2017 17h40 HE
|
Intellipharmaceutics International Inc.
TORONTO, May 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
24 mai 2017 16h05 HE
|
Intellipharmaceutics International Inc.
TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
10 mai 2017 15h17 HE
|
Intellipharmaceutics International Inc.
TORONTO, May 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Reports Director Election Results
18 avr. 2017 18h15 HE
|
Intellipharmaceutics International Inc.
TORONTO, April 18, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...